The global Bipolar Disorder Market was valued at $5.8 Billion in 2017 and is forecast to grow at a modest3.1 % CAGR between 2018 and 2025, culminating in 2025 global sales of $XXX.64 Billion.
Symptoms of bipolar disorder is a mental illness characterized by an extreme shift in mood, can include an extremely elevated mood called mania. It can have an episode of depression. People with bipolar disorder can have serious trouble managing daily life at office, school or work. As per the national institute of mental health (NIMH), 2.8% of U.S. adult have diagnosed with bipolar disorder and 4.4% have experienced at some time in their lives.
There are 3 main symptoms of bipolar disorder as mania, hypomania, and depression. Mania will lead to emotional high as unprotected sex, drug use etc. whereas hypomania will cause deep sadness, hopelessness, lack of interest in activities and suicidal thoughts. During the study, we observed a steep rise in the incidence of bipolar disorder in 5 states of USA, Germany, UK, Greece, Italy, and Spain. Though we have not noticed any major difference in trend between male and female, female will have a more frequent relapse due to hormonal changes.
Though the cause of bipolar disorder is not properly known to physicians, possible factors could be your genetics, abnormalities in the brain and environmental factor. There is no cure for bipolar disorder, but medications are there to control symptoms. It might need a combination of medication, physiotherapy, and psychoeducation.
Pricing Analysis
“Optimal Price Point (OPP) for Bipolar Disorder Drugs”
Estimated Average bipolar disorder drugs cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Product affordability and access to healthcare facilities are key variables impacting the market growth. The high demand for bipolar disorder drugs and other physiotherapy techniques in emerging nations is expected to drive the usage rates. The growing need for early diagnosis and government initiative is expected to lower the costs and improve the purchasing power of patients in this region.
Bipolar Disorder Market by “Drug Class”
Based on drug class, the market is segmented as Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety. Usage of tricyclic antidepressants for bipolar disorder has declined over the years due to its side effect profile. More than 60% of the market is dominated by antipsychotic drugs such as Aripiprazole (Abilify), Asenapine (Saphris), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal) etc. Some of the prominent mood stabilizers for bipolar disorder are Lithium, Valproate (Depakote), Carbamazepine (Tegretol), Gabapentin (Neurontin) etc. Carbamazepine is not approved by U.S. FDA but extensively used for bipolar disorder. Anticonvulsants work by calming hyperactivity and prescribed alone or in combination with antipsychotic drugs.
Bipolar Disorder Market by “Mechanism of Action”
Based on the mechanism of actions, the market is segmented as Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI), Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others. All antipsychotic drugs dominating treatment for bipolar disorder by Dopaminergic neurotransmission Inhibition. Selective serotonin reuptake inhibitors (SSRIs) ease depression by increasing serotonin level in the brain. Benzodiazepines are not considered as the1st line of treatment but prescribed in combination with other drugs to control the maniac symptoms.
Read Full Report @ https://www.ameriresearch.com/product/bipolar-disorder-market/
No comments:
Post a Comment